Your browser doesn't support javascript.
loading
CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.
Erin, Nuray; Dilmaç, Sayra; Curry, Anna; Duymus, Özlem; Tanriover, Gamze; Prodeus, Aaron; Gariepy, Jean; Gorczynski, Reginald M.
Afiliación
  • Erin N; Department of Medical Pharmacology, Immunopharmacology and Immunooncology Research unit, Akdeniz University School of Medicine, B-Blok Kat 1 Immunoloji, 07070, Antalya, Turkey. nerin@akdeniz.edu.tr.
  • Dilmaç S; Department of Histology and Embryology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Curry A; University Health Network, Toronto General Hospital, Toronto, Canada.
  • Duymus Ö; Department of Medical Pharmacology, Immunopharmacology and Immunooncology Research unit, Akdeniz University School of Medicine, B-Blok Kat 1 Immunoloji, 07070, Antalya, Turkey.
  • Tanriover G; Department of Histology and Embryology, Akdeniz University School of Medicine, Antalya, Turkey.
  • Prodeus A; Sunnybrook Cancer Centre, Toronto General Hospital, Toronto, Canada.
  • Gariepy J; Sunnybrook Cancer Centre, Toronto General Hospital, Toronto, Canada.
  • Gorczynski RM; University Health Network, Toronto General Hospital, Toronto, Canada.
Cancer Immunol Immunother ; 69(1): 103-114, 2020 Jan.
Article en En | MEDLINE | ID: mdl-31811336
We previously reported that CD200 overexpression in the host decreases progression and metastasis of the highly aggressive metastatic 4THM breast carcinoma. We have explored a possible synergistic interaction between the CD200 mimetic PEG-M49 and pegylated liposomal doxorubicin (Peg-Dox) in wild-type CD200 knockout (CD200-/-) and CD200 Receptor 1 knockout (CD200R1-/-) mice for the first time. A 4THM breast carcinoma model and three groups of BALB/c mice (wild type, CD200-/- and CD200R1-/-) were used. Five days after injection of tumor cells, mice were injected with Peg-Dox (ip, once a week) and PEG-M49 or a control aptamer (iv, every 3 days). Necropsies were performed either 12 (mid-point) or 24 (endpoint) days after injection and the extent of tumor growth, visceral metastasis and changes in the tumor-directed immune response were evaluated. PEG-M49 and Peg-Dox co-treatment induced complete tumor regression and loss of macroscopic lung metastasis in four out of seven WT mice. This synergistic anti-tumoral effect is thought to be due to Peg-M49-induced inhibition of Gr1 + CD11b + cells and Peg-Dox-induced increases in tumor-infiltrating CD8 + and CD8CD4 double-positive cells. Similar changes were observed in CD200R1-/- mice indicating that the primary effects of Peg-M49 are mediated by non-CD200R1 receptors. We also demonstrated for the first time that tumor growth, metastasis, and tumor infiltrating GR1 + CD11b + cells were markedly increased in CD200R1-/- mice, indicating an anti-inflammatory and protective role of CD200. CD200 mimetics might be a safe and effective immunomodulatory treatment in conjunction with classical chemotherapeutics for therapy of aggressive metastatic breast carcinoma.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Antígenos CD / Aptámeros de Nucleótidos Límite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Antígenos CD / Aptámeros de Nucleótidos Límite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2020 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Alemania